NZ508544A - Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide - Google Patents

Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide

Info

Publication number
NZ508544A
NZ508544A NZ508544A NZ50854499A NZ508544A NZ 508544 A NZ508544 A NZ 508544A NZ 508544 A NZ508544 A NZ 508544A NZ 50854499 A NZ50854499 A NZ 50854499A NZ 508544 A NZ508544 A NZ 508544A
Authority
NZ
New Zealand
Prior art keywords
magnesium oxide
quinapril
indolapril
enalapril
stabilised
Prior art date
Application number
NZ508544A
Other languages
English (en)
Inventor
Jane Ellen Daniel
Michael Ray Harris
Gerard Clifford Hokanson
Jay Weiss
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22210458&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ508544(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NZ508544A publication Critical patent/NZ508544A/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08Oxides; Hydroxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2009Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • A61K9/2018Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2068Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1611Inorganic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NZ508544A 1998-06-05 1999-05-10 Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide NZ508544A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8828098P 1998-06-05 1998-06-05
PCT/US1999/010189 WO1999062560A1 (en) 1998-06-05 1999-05-10 Stabilization of compositions containing ace inhibitors using magnesium oxide

Publications (1)

Publication Number Publication Date
NZ508544A true NZ508544A (en) 2002-10-25

Family

ID=22210458

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ508544A NZ508544A (en) 1998-06-05 1999-05-10 Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide

Country Status (32)

Country Link
US (3) US6417196B1 (https=)
EP (1) EP1083931B1 (https=)
JP (1) JP3727848B2 (https=)
KR (1) KR20010052557A (https=)
CN (1) CN1144598C (https=)
AR (1) AR019150A1 (https=)
AT (1) ATE295184T1 (https=)
AU (1) AU755616B2 (https=)
BR (1) BR9910947A (https=)
CA (1) CA2330581A1 (https=)
CO (1) CO5011043A1 (https=)
DE (1) DE69925269T2 (https=)
ES (1) ES2242398T3 (https=)
GT (1) GT199900079A (https=)
HK (1) HK1038879B (https=)
HN (1) HN1999000088A (https=)
HU (1) HUP0102260A3 (https=)
ID (1) ID27398A (https=)
IL (1) IL139590A0 (https=)
IS (1) IS2270B (https=)
MY (1) MY119667A (https=)
NO (1) NO20006148L (https=)
NZ (1) NZ508544A (https=)
PA (1) PA8475001A1 (https=)
PE (1) PE20000543A1 (https=)
PL (1) PL344586A1 (https=)
SV (1) SV1999000072A (https=)
TR (1) TR200003600T2 (https=)
TW (1) TW565455B (https=)
UY (1) UY25546A1 (https=)
WO (1) WO1999062560A1 (https=)
ZA (1) ZA200006537B (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2242398T3 (es) * 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor
GB0001621D0 (en) 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
US7867514B2 (en) * 2000-05-24 2011-01-11 Otsuka Pharmaceutical Co., Ltd. Method for stabilizing preparation
EA007981B1 (ru) * 2002-01-15 2007-02-27 Актавис Груп Хф. Фармацевтический состав, содержащий хинаприл или фармацевтически приемлемую его соль
US20030157165A1 (en) * 2002-02-01 2003-08-21 Sherman Bernard Charles Stable saccharide-free tablets comprising a salt of quinapril or moexipril
WO2004073729A1 (ja) 2003-02-21 2004-09-02 Translational Research Ltd. 薬物の経鼻投与用組成物
CA2519287A1 (en) 2003-03-27 2004-10-14 Bioactis Limited Powder medicine applicator for nasal cavity
CZ298224B6 (cs) * 2003-04-29 2007-07-25 Pliva Istrazivanje I Razvoj D.O.O. Farmaceutická kompozice obsahující jako úcinnou látku ribavirin a zpusob její výroby
ES2322854T3 (es) * 2003-06-26 2009-06-30 Teva Pharmaceutical Industries Limited Composiciones farmaceuticas estables de derivados del acido 2-aza-biciclo(3.3.0)-octano-3-carboxilico.
WO2006016530A1 (ja) * 2004-08-10 2006-02-16 Translational Research, Ltd. 速効性でかつ高い吸収性を可能とする経鼻投与用組成物
US7799937B2 (en) 2004-10-25 2010-09-21 Synthonics, Inc. Metal coordinated compositions
US20060141054A1 (en) 2004-10-25 2006-06-29 Thomas Piccariello Metal coordinated compositions
US8779175B2 (en) 2004-10-25 2014-07-15 Synthonics, Inc. Coordination complexes, pharmaceutical solutions comprising coordination complexes, and methods of treating patients
ITMI20060026A1 (it) * 2006-01-10 2007-07-11 Truffini & Regge Farmaceutici Srl Composizioni per uso rale a base di s-adenosilmetionina e processo per il loro ottenimento
EP1815857A1 (en) 2006-02-02 2007-08-08 LEK Pharmaceuticals D.D. A pharmaceutical composition comprising perindopril
US20070232680A1 (en) * 2006-04-04 2007-10-04 Vijayabhaskar Bolugoddu Preparation of ramipril and stable pharmaceutical compositions
US20080015188A1 (en) * 2006-04-19 2008-01-17 Julia Hrakovsky Stable pharmaceutical compositions of 2-aza-bicyclo(3.3.0)-octane-3-carboxylic acid derivatives
AU2007264414A1 (en) * 2006-06-30 2008-01-03 Alphapharm Pty Ltd A stabilised composition comprising ACE inhibitors
US20080071141A1 (en) * 2006-09-18 2008-03-20 Abhisuek Gattani Method and apparatus for measuring attributes of an anatomical feature during a medical procedure
CN101668544B (zh) 2006-12-26 2013-04-24 株式会社新日本科学 经鼻投用制剂
WO2008132756A1 (en) * 2007-05-01 2008-11-06 Lupin Limited Stable pharmaceutical compositions of ramipril
JP5113476B2 (ja) * 2007-10-09 2013-01-09 沢井製薬株式会社 保存安定性に優れた塩酸テモカプリルの錠剤
US9101539B2 (en) * 2009-05-15 2015-08-11 Shin Nippon Biomedical Laboratories, Ltd. Intranasal pharmaceutical compositions with improved pharmacokinetics
GB2472327B (en) 2009-07-31 2013-03-13 Shin Nippon Biomedical Lab Ltd Intranasal granisetron and nasal applicator
TR200906322A2 (tr) 2009-08-17 2011-07-21 Bi̇lgi̇ç Mahmut Çözünürlük ve stabilite özellikleri geliştirilmiş granüller.
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
TN2010000566A1 (en) * 2010-12-03 2012-05-24 Rekik Raouf Folic acid - ramipril combination : cell protective neuroprotective and retinoprotective ophtalmologic drugs
CN102512656B (zh) * 2011-12-27 2013-11-27 天津市嵩锐医药科技有限公司 盐酸喹那普利药物组合物
US11744967B2 (en) 2017-09-26 2023-09-05 Shin Nippon Biomedical Laboratories, Ltd. Intranasal delivery devices

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320029A (en) * 1967-05-16 Method of preparing magnesia
IL58849A (en) * 1978-12-11 1983-03-31 Merck & Co Inc Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them
US4344949A (en) * 1980-10-03 1982-08-17 Warner-Lambert Company Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids
US4425355A (en) * 1981-02-17 1984-01-10 Warner-Lambert Company Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids
US4793998A (en) 1986-10-20 1988-12-27 Warner-Lambert Company Stabilized drug compositions
US4830853A (en) * 1986-10-20 1989-05-16 Warner-Lambert Company Drug compositions stabilized against oxidation
US4743450A (en) 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4830583A (en) * 1988-03-02 1989-05-16 Sri International Fluid motor-pumping apparatus and system
US5622985A (en) * 1990-06-11 1997-04-22 Bristol-Myers Squibb Company Method for preventing a second heart attack employing an HMG CoA reductase inhibitor
HU222489B1 (hu) 1990-07-25 2003-07-28 Novartis Ag. Stabilizált gyógyszerkészítmények és eljárás az előállításukra
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
JP3414539B2 (ja) * 1994-05-11 2003-06-09 有限会社ドット 経鼻吸収用組成物
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
ES2242398T3 (es) * 1998-06-05 2005-11-01 Warner-Lambert Company Llc Estabilizacion de composiciones que contienen inhibidores de la enzima de conversion de la angiotensina utilizando oxido de magnesio.
NZ333206A (en) * 1998-12-08 2000-07-28 Bernard Charles Sherman Solid pharmaceutical compositions comprising a stable magnesium salt of quinapril that acts as a ACE (Angiotensin Converting Enzyme) inhibitor

Also Published As

Publication number Publication date
CO5011043A1 (es) 2001-02-28
US20020161020A1 (en) 2002-10-31
HK1038879A1 (en) 2002-04-04
JP2002516881A (ja) 2002-06-11
DE69925269T2 (de) 2006-02-23
ES2242398T3 (es) 2005-11-01
GT199900079A (es) 2000-11-25
SV1999000072A (es) 2000-05-04
US6417196B1 (en) 2002-07-09
US20060106057A1 (en) 2006-05-18
DE69925269D1 (de) 2005-06-16
HUP0102260A3 (en) 2002-12-28
ATE295184T1 (de) 2005-05-15
US7015232B2 (en) 2006-03-21
AU755616B2 (en) 2002-12-19
NO20006148D0 (no) 2000-12-04
NO20006148L (no) 2000-12-04
ZA200006537B (en) 2001-11-12
PL344586A1 (en) 2001-11-05
EP1083931A1 (en) 2001-03-21
CN1304322A (zh) 2001-07-18
CN1144598C (zh) 2004-04-07
BR9910947A (pt) 2001-03-06
JP3727848B2 (ja) 2005-12-21
IS2270B (is) 2007-07-15
HUP0102260A2 (hu) 2002-03-28
KR20010052557A (ko) 2001-06-25
TW565455B (en) 2003-12-11
AU3979399A (en) 1999-12-20
IS5712A (is) 2000-11-10
IL139590A0 (en) 2002-02-10
ID27398A (id) 2001-04-05
WO1999062560A1 (en) 1999-12-09
HN1999000088A (es) 2000-02-10
CA2330581A1 (en) 1999-12-09
EP1083931B1 (en) 2005-05-11
PE20000543A1 (es) 2000-08-10
TR200003600T2 (tr) 2001-04-20
HK1038879B (zh) 2004-10-08
PA8475001A1 (es) 2000-09-29
UY25546A1 (es) 1999-09-27
AR019150A1 (es) 2001-12-26
MY119667A (en) 2005-06-30

Similar Documents

Publication Publication Date Title
NZ508544A (en) Angiotensin converting enzyme inhibitors, such as quinapril, enalapril and indolapril, stabilised with 1-90 wt% magnesium oxide
EP2409985A3 (en) Inhibitors de serine proteases, especially of the NS3 protease of the hepatitis C virus
YU8502A (sh) Inhibitori sistema renin-angiotenzin i njihova primena
WO2003045418A1 (en) Medicinal compositions for nasal absorption
UA87434C2 (ru) Циклоалкильные соединения в качестве ингибиторов функции калиевых каналов
CA2130577A1 (en) Combinations of ace inhibitors and diuretics
WO2004043339A3 (en) Substituted cycloalkyl p1' hepatitis c virus inhibitors
WO2005034908A3 (en) A solid dosage form comprising a fibrate and a statin
HK1048808A1 (zh) 杂环二羟嘧啶作为钾血管抑制剂
WO2002060926A3 (en) Hepatitis c tripeptide inhibitors
WO2000055124A3 (en) Novel compounds and compositions as protease inhibitors
AR046255A1 (es) Composiciones farmaceuticas estables que contienen un inhibidor de enzima de conversion de angiotensina
WO2001003684A3 (en) Albumin-binding compounds that prevent nonenzymatic glycation and that may be used for treatment of glycation-related pathologies
WO2002033050A3 (en) Methods and compositions for promoting the maturation of monocytes
EP1503798B8 (en) Stabilised solid compositions of modified factor vii
US20020013338A1 (en) Stabilized pharmaceutical compositions comprising acid donors
TW200503690A (en) Pharmaceutical compositions of atorvastatin
WO2005020970A3 (en) Protease inhibitor compositions for prevention and treatment of skin conditions
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
IL151888A0 (en) Granulated particles with masked taste
IL98934A (en) Stable pharmaceutical compositions and their preparation
WO2001080715A3 (en) Methods for identifying compounds useful for preventing acute clinical vascular events in a subject
WO2004032708A3 (en) Vasoregulating compounds and methods of their use
AU2001252419A1 (en) Thrombin inhibitors
IL144006A0 (en) Pharmaceutical mixture comprising a combination of a profen and other active compounds

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)